A government watchdog agency is conducting three new reviews of the Medicaid Drug Rebate Program to determine the extent to which drug companies are properly paying required givebacks to the health care program.
After EpiPen Controversy, Watchdog to Review Medicaid Rebates
Comment
Show comments
Hide Comments
